Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is one of the 10 Most Undervalued Foreign Stocks to Buy According to Analysts. Morgan Stanley reduced its price target from $166 to $165 but maintained a ‘Buy’ rating due to expectations of a rebound in the second half of the year.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is anticipated to see significant clinical developments and a leadership change, with an oncology revenue estimate that surpasses street estimates. Wells Fargo also maintained a ‘Buy’ rating with a price target of $170 on July 18.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) operates globally, developing and commercializing pharmaceutical products. Despite being undervalued, some believe other AI stocks offer greater upside potential and less downside risk. For more information on a potentially undervalued AI stock, see the free report on the best short-term AI stock.

Read more at Yahoo Finance: Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating